Referral Patterns and Treatment Choices for Patients with Hepatocellular Carcinoma: A United States Population-Based Study

被引:44
作者
Hyder, Omar [1 ]
Dodson, Rebecca M. [1 ]
Nathan, Hari [1 ]
Herman, Joseph M. [2 ]
Cosgrove, David [3 ]
Kamel, Ihab [4 ]
Geschwind, Jean-Francois H. [5 ]
Pawlik, Timothy M. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Dept Med Oncol, Baltimore, MD USA
[4] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA
[5] Johns Hopkins Univ, Sch Med, Dept Intervent Radiol, Baltimore, MD USA
关键词
LOCOREGIONAL ESOPHAGEAL CANCER; IMPACT; DISPARITIES; SURVIVAL; MORTALITY; AGE; EPIDEMIOLOGY; MANAGEMENT; OUTCOMES; THERAPY;
D O I
10.1016/j.jamcollsurg.2013.07.007
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Patterns of care of physician specialists may differ for patients with hepatocellular carcinoma (HCC). Reasons underlying variations are poorly understood. One source of variation may be disparate referral rates to specialists, leading to differences in cancer-directed treatments. STUDY DESIGN: Surveillance, Epidemiology, and End Results (SEER)-linked Medicare database was queried for patients with HCC, diagnosed between 1998 and 2007, who consulted 1 or more physicians after diagnosis. Visit and procedure records were abstracted from Medicare billing records. Factors associated with specialist consult and subsequent treatment were examined. RESULTS: There were 6,752 patients with HCC identified; 1,379 (20%) patients had early-stage disease. Median age was 73 years; the majority were male (66%), white (60%), and from the West region (56%). After diagnosis, referral to a specialist varied considerably (hepatology/gastroenterology, 60%; medical oncology, 62%; surgery, 56%; interventional radiology [IR], 33%; radiation oncology, 9%). Twenty-two percent of patients saw 1 specialist; 39% saw 3 or more specialists. Time between diagnosis and visitation with a specialist varied (surgery, 37 days vs IR, 55 days; p = 0.04). Factors associated with referral to a specialist included younger age (odds ratio [OR] 2.16), Asian race (OR 1.49), geographic region (Northeast OR 2.10), and presence of early-stage disease (OR 2.21) (all p < 0.05). Among patients with early-stage disease, 77% saw a surgeon, while 50% had a consultation with medical oncologist. Receipt of therapy among patients with early-stage disease varied (no therapy, 30%; surgery, 39%; IR, 9%; chemotherapy, 23%). Factors associated with receipt of therapy included younger age (OR 2.48) and early-stage disease (OR 2.20). CONCLUSIONS: After HCC diagnosis, referral to a specialist varied considerably. Both clinical and nonclinical factors were associated with consultation. Disparities in referral to a specialist and subsequent therapy need to be better understood to ensure all HCC patients receive appropriate care. ((C) 2013 by the American College of Surgeons)
引用
收藏
页码:896 / 906
页数:11
相关论文
共 34 条
[1]   Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005 [J].
Altekruse, Sean F. ;
McGlynn, Katherine A. ;
Reichman, Marsha E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1485-1491
[2]  
Bach PB, 2002, MED CARE, V40, P19
[3]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[4]   Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation [J].
Cabibbo, G. ;
Genco, C. ;
Di Marco, V. ;
Barbara, M. ;
Enea, M. ;
Parisi, P. ;
Brancatelli, G. ;
Romano, P. ;
Craxi, A. ;
Camma, C. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (02) :196-204
[5]   Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study [J].
Dhanasekaran, Renumathy ;
Kooby, David A. ;
Staley, Charles A. ;
Kauh, John S. ;
Khanna, Vinit ;
Kim, Hyun S. .
HPB, 2010, 12 (03) :174-180
[6]   Impact of referral patterns on the use of chemotherapy for lung cancer [J].
Earle, CC ;
Neumann, PJ ;
Gelber, RD ;
Weinstein, MC ;
Weeks, JC .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1786-1792
[7]   Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis [J].
El-Serag, Hashem B. ;
Rudolph, Lenhard .
GASTROENTEROLOGY, 2007, 132 (07) :2557-2576
[8]   Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma [J].
El-Serag, Hashem B. .
GASTROENTEROLOGY, 2012, 142 (06) :1264-+
[9]   Comorbidity measures for use with administrative data [J].
Elixhauser, A ;
Steiner, C ;
Harris, DR ;
Coffey, RN .
MEDICAL CARE, 1998, 36 (01) :8-27
[10]   Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer [J].
Hodgson, DC ;
Fuchs, CS ;
Ayanian, JZ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (07) :501-515